Epiroprim

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 461373

CAS#: 73090-70-7

Description: Epiroprim is an analog of trimethoprim and an inhibitor of dihydrofolate reductase.

Chemical Structure

img
Epiroprim
CAS# 73090-70-7
Instruction

Theoretical Analysis

MedKoo Cat#: 461373
Name: Epiroprim
CAS#: 73090-70-7
Chemical Formula: C19H23N5O2
Exact Mass: 353.19
Molecular Weight: 353.420
Elemental Analysis: C, 64.57; H, 6.56; N, 19.82; O, 9.05

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Epiroprim; Epiroprime; Ro 11-8958; Ro-11-8958; Ro11-8958;

IUPAC/Chemical Name: 5-(3,5-diethoxy-4-(1H-pyrrol-1-yl)benzyl)pyrimidine-2,4-diamine

InChi Key: NMARPFMJVCXSAV-UHFFFAOYSA-N

InChi Code: InChI=1S/C19H23N5O2/c1-3-25-15-10-13(9-14-12-22-19(21)23-18(14)20)11-16(26-4-2)17(15)24-7-5-6-8-24/h5-8,10-12H,3-4,9H2,1-2H3,(H4,20,21,22,23)

SMILES Code: CCOC1=C(N2C=CC=C2)C(OCC)=CC(CC3=CN=C(N)N=C3N)=C1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 353.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Martinez A, Allegra CJ, Kovacs JA. Efficacy of epiroprim (Ro11-8958), a new dihydrofolate reductase inhibitor, in the treatment of acute Toxoplasma infection in mice. Am J Trop Med Hyg. 1996 Mar;54(3):249-52. PubMed PMID: 8600759.

2: Dhople AM. In vitro activity of epiroprim, a dihydrofolate reductase inhibitor, singly and in combination with brodimoprim and dapsone, against Mycobacterium leprae. Int J Antimicrob Agents. 1999 Aug;12(4):319-23. PubMed PMID: 10493608.

3: Chang HR, Arsenijevic D, Comte R, Polak A, Then RL, Pechère JC. Activity of epiroprim (Ro 11-8958), a dihydrofolate reductase inhibitor, alone and in combination with dapsone against Toxoplasma gondii. Antimicrob Agents Chemother. 1994 Aug;38(8):1803-7. PubMed PMID: 7986011; PubMed Central PMCID: PMC284639.

4: Luttringer O, Theil FP, Poulin P, Schmitt-Hoffmann AH, Guentert TW, Lavé T. Physiologically based pharmacokinetic (PBPK) modeling of disposition of epiroprim in humans. J Pharm Sci. 2003 Oct;92(10):1990-2007. PubMed PMID: 14502539.

5: Locher HH, Schlunegger H, Hartman PG, Angehrn P, Then RL. Antibacterial activities of epiroprim, a new dihydrofolate reductase inhibitor, alone and in combination with dapsone. Antimicrob Agents Chemother. 1996 Jun;40(6):1376-81. PubMed PMID: 8726004; PubMed Central PMCID: PMC163334.

6: Lee HS, Chang HR, Khoo YM. Simple HPLC determination of the concentrations of epiroprim in the serum and brains of mice. J Pharm Pharmacol. 1996 Oct;48(10):1090-2. PubMed PMID: 8953514.

7: N'guessan K, Dosso M, Marchal G, Chavarot P, Romain F, Pescher P, Edy. [Preliminary study on isoniazid-epiroprim combination in a tuberculosis murine model]. Bull Soc Pathol Exot. 2002 Nov;95(4):265-8. French. PubMed PMID: 12596375.

8: Dosso M, Ouattara L, Cherif AM, Bouzid SA, Haller L, Fernex M. Experimental in vitro efficacy study on the interaction of epiroprim plus isoniazid against Mycobacterium tuberculosis. Chemotherapy. 2001 Mar-Apr;47(2):123-7. PubMed PMID: 11173814.

9: Mehlhorn H, Dankert W, Hartman PG, Then RL. A pilot study on the efficacy of epiroprim against developmental stages of Toxoplasma gondii and Pneumocystis carinii in animal models. Parasitol Res. 1995;81(4):296-301. PubMed PMID: 7624286.

10: Brun-Pascaud M, Chau F, Garry L, Jacobus D, Derouin F, Girard PM. Combination of PS-15, epiroprim, or pyrimethamine with dapsone in prophylaxis of Toxoplasma gondii and Pneumocystis carinii dual infection in a rat model. Antimicrob Agents Chemother. 1996 Sep;40(9):2067-70. PubMed PMID: 8878582; PubMed Central PMCID: PMC163474.

11: Dhople AM. In vivo activity of epiroprim, a dihydrofolate reductase inhibitor, singly and in combination with dapsone, against Mycobacterium leprae. Int J Antimicrob Agents. 2002 Jan;19(1):71-4. PubMed PMID: 11814771.

12: Dhople AM. Antimicrobial activities of dihydrofolate reductase inhibitors, used singly or in combination with dapsone, against Mycobacterium ulcerans. J Antimicrob Chemother. 2001 Jan;47(1):93-6. PubMed PMID: 11152437.

13: Sayama H, Komura H, Kogayu M. Application of hybrid approach based on empirical and physiological concept for predicting pharmacokinetics in humans--usefulness of exponent on prospective evaluation of predictability. Drug Metab Dispos. 2013 Feb;41(2):498-507. doi: 10.1124/dmd.112.048819. Epub 2012 Dec 3. PubMed PMID: 23209193.

14: Gangjee A, Vasudevan A, Queener SF. Synthesis and biological evaluation of nonclassical 2,4-diamino-5-methylpyrido[2,3-d]pyrimidines with novel side chain substituents as potential inhibitors of dihydrofolate reductases. J Med Chem. 1997 Feb 14;40(4):479-85. PubMed PMID: 9046338.

15: Walzer PD, Runck J, Steele P, White M, Linke MJ, Sidman CL. Immunodeficient and immunosuppressed mice as models to test anti-Pneumocystis carinii drugs. Antimicrob Agents Chemother. 1997 Feb;41(2):251-8. PubMed PMID: 9021175; PubMed Central PMCID: PMC163697.

16: Walzer PD, Foy J, Steele P, White M. Synergistic combinations of Ro 11-8958 and other dihydrofolate reductase inhibitors with sulfamethoxazole and dapsone for therapy of experimental pneumocystosis. Antimicrob Agents Chemother. 1993 Jul;37(7):1436-43. PubMed PMID: 8363372; PubMed Central PMCID: PMC187990.